Wolfgang H. Jost
#160,386
Most Influential Person Now
Wolfgang H. Jost's AcademicInfluence.com Rankings
Wolfgang H. Jostphilosophy Degrees
Philosophy
#9226
World Rank
#12755
Historical Rank
Logic
#6213
World Rank
#7707
Historical Rank

Wolfgang H. Jostbiology Degrees
Biology
#12661
World Rank
#16152
Historical Rank
Neuroscience
#2137
World Rank
#2197
Historical Rank

Download Badge
Philosophy Biology
Wolfgang H. Jost's Degrees
- PhD Neuroscience University of Vienna
- Doctorate Medicine University of Vienna
Why Is Wolfgang H. Jost Influential?
(Suggest an Edit or Addition)Wolfgang H. Jost's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Vulnerability of the nigrostriatal system as detected by transcranial ultrasound (1999) (326)
- A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia (2005) (250)
- Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm (2006) (241)
- One hundred cases of anal fissure treated with botulin toxin (1997) (220)
- Nonmotor fluctuations in Parkinson disease (2013) (203)
- Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. (2007) (180)
- Striatal FP-CIT uptake differs in the subtypes of early Parkinson’s disease (2007) (158)
- Early diagnosis of Parkinson’s disease (2006) (144)
- Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial (2017) (143)
- Gastrointestinal Motility Problems in Patients with Parkinson’s Disease (1997) (140)
- Is levodopa toxic? (2004) (131)
- Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease. (2006) (126)
- Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm (2001) (117)
- Botulinum toxin: clinical use. (2006) (116)
- FP‐CIT and MIBG scintigraphy in early Parkinson's disease (2005) (115)
- Botulinum Neurotoxin Type A Free of Complexing Proteins (XEOMIN®) in Focal Dystonia (2012) (113)
- Therapy of anal fissure using botulin toxin (1994) (106)
- Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson's disease (2007) (104)
- Gastrointestinal dysfunction in Parkinson's Disease (2010) (97)
- Treatment of drooling in Parkinson's disease with botulinum toxin (1999) (95)
- Classification of posture in poststroke upper limb spasticity: a potential decision tool for botulinum toxin A treatment? (2012) (93)
- A common mutation (ε1267delG) in congenital myasthenic patients of Gypsy ethnic origin (1999) (90)
- Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX°) in healthy volunteers (2005) (83)
- Autonomic dysfunctions in idiopathic Parkinson's disease (2003) (83)
- Use of botulinum toxin in anal fissure (1993) (81)
- The profile of patients and current practice of treatment of upper limb muscle spasticity with botulinum toxin type A: an international survey (2010) (79)
- Rating scales for cervical dystonia: a critical evaluation of tools for outcome assessment of botulinum toxin therapy (2012) (79)
- Evidence-based medicine: botulinum toxin A in migraine and tension-type headache (2001) (76)
- α-Synuclein in Parkinson’s disease: causal or bystander? (2019) (71)
- Perianal thrombosis following injection therapy into the external anal sphincter using botulin toxin (1995) (59)
- Botulinum toxin in the treatment of neurological disorders of the autonomic nervous system. (1999) (58)
- Botulinum toxin treatment of secretory disorders (2004) (57)
- Repeat Botulin Toxin Injections in Anal Fissure (In Patients with Relapse and After Insufficient Effect of First Treatment) (1999) (55)
- Defecatory disorders in de novo Parkinsonians--colonic transit and electromyogram of the external anal sphincter. (1998) (55)
- Botulinum toxin in therapy of anal fissure (1995) (54)
- Quantitative assessment of non-motor fluctuations in Parkinson’s disease using the Non-Motor Symptoms Scale (NMSS) (2015) (50)
- Nondipping in Parkinson's Disease (2011) (49)
- The Parkinson–Control study: A 1‐year randomized, double‐blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease (2006) (49)
- Lewy body dementia and Parkinson’s disease with dementia (2008) (49)
- Utility of the WHO‐five well‐being index as a screening tool for depression in Parkinson's disease (2010) (48)
- Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson’s disease: a systematic review (2009) (46)
- Long‐term results with cisapride in Parkinson's disease (1997) (45)
- Eye movement in amyotrophic lateral sclerosis: a longitudinal study. (1995) (45)
- Constipation in Parkinson's disease (1991) (45)
- Relevance of sonography for botulinum toxin treatment of cervical dystonia: an expert statement (2014) (45)
- SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea (2019) (44)
- Duloxetine: mechanism of action at the lower urinary tract and Onuf’s nucleus (2004) (43)
- A common mutation (epsilon1267delG) in congenital myasthenic patients of Gypsy ethnic origin. (1999) (42)
- Nonmotor symptoms and focal cervical dystonia: Observations from 102 patients (2014) (40)
- Ten years' experience with botulin toxin in anal fissure (2002) (40)
- The phenylalanine loading test in the differential diagnosis of dystonia (2003) (39)
- A new method to determine pudendal nerve motor latency and central motor conduction time to the external anal sphincter. (1993) (37)
- Difficulties with differentiating botulinum toxin treatment effects in essential blepharospasm (2011) (36)
- Constipation in idiopathic Parkinson's disease. (2003) (36)
- Autonomic Disorders in Multiple Sclerosis (2011) (36)
- Magnetic stimulation of the pudendal nerve (1994) (35)
- Arrested cerebral adrenoleukodystrophy: a clinical and proton magnetic resonance spectroscopy study in three patients. (1996) (35)
- Ropinirole, a non-ergoline dopamine agonist. (2006) (35)
- Botulinum toxin: evidence-based medicine criteria in rare indications (2001) (35)
- An open-label cohort study of the improvement of quality of life and pain in de novo cervical dystonia patients after injections with 500 U botulinum toxin A (Dysport) (2013) (35)
- Urological problems in Parkinson’s disease: clinical aspects (2013) (34)
- Advanced stages of PD: interventional therapies and related patient-centered care (2015) (33)
- Functional outlet obstruction: anismus, spastic pelvic floor syndrome, and dyscoordination of the voluntary sphincter muscles. Definition, diagnosis, and treatment from the neurologic point of view. (1999) (33)
- Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized‐controlled trial (2016) (32)
- Selection of Muscles for Botulinum Toxin Injections in Cervical Dystonia (2015) (32)
- Botulinum toxin in tension-type headache (2004) (31)
- Depression in Parkinson’s disease (2001) (31)
- The option of sonographic guidance in Botulinum toxin injection for drooling in Parkinson’s disease (2015) (30)
- [Non-motor Symptoms Questionnaire and Scale for Parkinson's disease. Cross-cultural adaptation into the German language]. (2010) (29)
- The effect of cisapride on delayed colonic transit time in patients with idiopathic Parkinson's disease. (1994) (29)
- Differentiation of atypical Parkinson syndromes (2017) (29)
- Parkinson’s disease between internal medicine and neurology (2015) (29)
- Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders (2015) (28)
- Importance of 123I-Metaiodobenzylguanidine Scintigraphy/Single Photon Emission Computed Tomography for Diagnosis and Differential Diagnostics of Parkinson Syndromes (2010) (28)
- Influence of the Nonergot Dopamine Agonist Piribedil on Vigilance in Patients With Parkinson Disease and Excessive Daytime Sleepiness (PiViCog-PD): An 11-Week Randomized Comparison Trial Against Pramipexole and Ropinirole (2014) (27)
- Efficacy and safety of botulinum toxin type A (Dysport) for the treatment of post-stroke arm spasticity: Results of the German–Austrian open-label post-marketing surveillance prospective study (2014) (27)
- Anatomy and cervical dystonia (2017) (26)
- Pramipexole Extended Release: A Novel Treatment Option in Parkinson's Disease (2010) (26)
- Efficacy and tolerability of rasagiline in daily clinical use – a post‐marketing observational study in patients with Parkinson’s disease (2010) (26)
- Current state of stem cell research for the treatment of Parkinson's disease (2002) (26)
- Gastrointestinal involvement in Parkinson’s disease: pathophysiology, diagnosis, and management (2022) (25)
- Duloxetine in the treatment of stress urinary incontinence (2005) (25)
- Safinamide Add on to L-Dopa: A Randomized, Placebo-Controlled, 24-Week Global Trial in Patients with Parkinson's Disease (PD) and Motor Fluctuations (SETTLE) (P01.062) (2013) (25)
- A botulinum toxin A treatment algorithm for de novo management of torticollis and laterocollis (2011) (25)
- Dynamics of Parkinson’s Disease Multimodal Complex Treatment in Germany from 2010–2016: Patient Characteristics, Access to Treatment, and Formation of Regional Centers (2019) (25)
- Costs in the treatment of parkinsonism (2000) (24)
- Botulinum toxin in patients with multiple sclerosis (2006) (24)
- Severity of orthostatic hypotension in the course of Parkinson's disease: no correlation with the duration of the disease. (2015) (23)
- Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson’s Disease Patients (2019) (23)
- Autonome Regulationsstrungen beim Parkinson-Syndrom (1995) (22)
- [Nonmotor symptoms in Parkinson's disease]. (2017) (22)
- Colonic transit time in nonidiopathic Parkinson's syndrome. (1994) (22)
- A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial (2020) (21)
- Autonomic nervous system dysfunction in lightning and electrical injuries. (2005) (21)
- Frequency of different subtypes of cervical dystonia: a prospective multicenter study according to Col–Cap concept (2019) (21)
- Therapy of anal fissure using botulin toxin (1994) (21)
- Long-term incobotulinumtoxinA treatment for chronic sialorrhea: Efficacy and safety over 64 weeks. (2019) (21)
- Autonomic Dysfunction in Parkinson's Disease: Cardiovascular Symptoms, Thermoregulation, and Urogenital Symptoms. (2017) (21)
- Therapy of Sialorrhea with Botulinum Neurotoxin (2019) (20)
- Indirect meta-analysis of randomised placebo-controlled clinical trials on rasagiline and selegiline in the symptomatic treatment of Parkinson's disease (2012) (19)
- Assessment of Nonmotor Fluctuations Using a Diary in Advanced Parkinson's disease. (2016) (18)
- Botulinum toxin in multiple sclerosis (2006) (18)
- Surface versus needle electrodes in determination of motor conduction time to the external anal sphincter (2004) (18)
- Early Detection of Parkinson’s Disease: Unmet Needs (2008) (17)
- SIAXI (2019) (17)
- Hypersalivation: update of the German S2k guideline (AWMF) in short form (2019) (16)
- Electrostimulation in fecal incontinence (1998) (16)
- Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration (2014) (16)
- Interkulturelle Adaptation des Survey of Autonomic Symptoms (SAS) (2012) (16)
- [Therapy and care of patients with chronic migraine: expert recommendations of the German Migraine and Headache Society/German Society for Neurology as well as the Austrian Headache Society/Swiss Headache Society]. (2012) (16)
- Autonomic disturbances including impaired hand thermoregulation in multiple system atrophy and Parkinson’s disease (2017) (15)
- Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study (2020) (15)
- [Characteristics and dynamics of inpatient treatment of patients with Parkinson's disease in Germany : Analysis of 1.5 million patient cases from 2010 to 2015]. (2019) (15)
- Reduced Body Mass Index in Parkinson’s Disease: Contribution of Comorbid Depression (2013) (15)
- Drug interactions in the treatment of Parkinson's disease (2002) (15)
- Drug-induced impulse control disorders in Parkinson’s disease (2011) (15)
- The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: Clinical cases and a review of the literature (2021) (15)
- Botulinum toxin in neuro‐urological disorders (2004) (15)
- Shock Waves and Detonations in Gases (1968) (15)
- [Clinical use of botulinum toxin]. (2008) (14)
- [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy]. (2007) (14)
- Evidence-based medicine (EBM) (2001) (13)
- Cervical dystonia - improving the effectiveness of botulinum toxin therapy. (2020) (13)
- Timing and Kinetics of Nonmotor Fluctuations in Advanced Parkinson's Disease. (2017) (13)
- Analyse der direkten Kosten in der Parkinson-Therapie (2003) (13)
- EMG of the external anal sphincter: Needle is superior to surface electrode (2000) (13)
- The challenge of pain in the pharmacological management of Parkinson’s disease (2019) (12)
- A Pilot Prospective, Multicenter Observational Study of Dopamine Agonist Withdrawal Syndrome in Parkinson's Disease (2015) (12)
- Botulinum toxin type B in the treatment of anal fissures: First preliminary results (2001) (12)
- Ropinirole: Current status of the studies (2004) (11)
- Involuntary contractions of the striated anal sphincters as a cause of constipation (1998) (11)
- “An essay on the shaking palsy” 200 years old (2017) (11)
- [Depression in Parkinson's disease. Part 1: epidemiology, signs and symptoms, pathophysiology and diagnosis]. (2008) (11)
- The impact of ropinirole on blood pressure and noradrenaline concentration after active orthostasis in Parkinsonian patients. (1998) (11)
- [Parkinson's Disease at the Border Between Inpatient and Outpatient Care]. (2016) (11)
- [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment]. (2008) (10)
- Intraindividual Variability of Nonmotor Fluctuations in Advanced Parkinson's Disease. (2015) (10)
- King’s Parkinson’s Disease Pain Scale (2018) (10)
- Influence of levodopa on orthostatic hypotension in Parkinson's Disease. (2020) (10)
- Cerebral and Extracranial Neurodegeneration are Strongly Coupled in Parkinson’s Disease (2007) (10)
- Individualized OnabotulinumtoxinA Treatment for Upper Limb Spasticity Resulted in High Clinician‐ and Patient‐Reported Satisfaction: Long‐Term Observational Results from the ASPIRE Study (2020) (9)
- Management of Pain in Parkinson’s Disease (2020) (9)
- Preferred muscles in cervical dystonia. (2020) (9)
- Botulinum toxin in painful diseases (2003) (8)
- An update on the recognition and treatment of autonomic symptoms in Parkinson’s disease (2017) (8)
- Tau Imaging in the 4-Repeat-Tauopathies Progressive Supranuclear Palsy and Corticobasal Syndrome: A 11C-Pyridinyl-Butadienyl-Benzothiazole 3 PET Pilot Study. (2020) (8)
- [Botulinum toxin in specific pain therapy]. (2003) (8)
- [Gastrointestinal dysfunction in idiopathic Parkinson's disease]. (2012) (8)
- [Prospective study of the direct and indirect costs of idiopathic Parkinson's disease]. (2006) (8)
- Clinical studies with ropinirole in Parkinson’s disease and RLS (2006) (8)
- [Hypersalivation - inauguration of the S2k Guideline (AWMF) in short form]. (2013) (7)
- A tribute to Wilhelm H. Erb (2006) (7)
- Improvement of SF-36 scores in cervical dystonia patients—Is there a treatment effect when evaluating subscales? (2014) (7)
- Dyskinesia in multiple system atrophy and progressive supranuclear palsy (2019) (7)
- [Pharmaceutical treatment of stress incontinence. New approaches via a direct effect of duloxetine on Onuf's nucleus]. (2004) (7)
- [Urinary incontinence in patients with Parkinson syndrome]. (1996) (7)
- Implications of dopaminergic medication withdrawal in Parkinson’s disease (2021) (7)
- Injection into the Longus Colli Muscle via the Thyroid Gland (2019) (7)
- Adult Spasticity International Registry Study: methodology and baseline patient, healthcare provider, and caregiver characteristics. (2017) (7)
- Somatosensory evoked potentials of the pudendal nerve in penile hypoesthesia. (1998) (7)
- [Electrophysiologic diagnosis in erectile dysfunction]. (1996) (7)
- A critical appraisal of MAO-B inhibitors in the treatment of Parkinson’s disease (2022) (6)
- Influence of botulinum toxin injections on the sphincteric compound muscle action potential of the external anal sphincter (1997) (6)
- Efficacy and safety of botulinum neurotoxin type A free of complexing proteins (NT 201) in cervical dystonia and blepharospasm (2007) (6)
- Incidence of anal fissure in nonselected neurological patients (1999) (6)
- [Analysis of direct costs in therapy of Parkinson disease]. (2003) (6)
- Therapeutic approaches to Lambert-Eaton myasthenic syndrome in the intra-individual comparison. (1991) (6)
- Rasagilin im klinischen Alltag (2008) (6)
- Drug interactions with selegiline versus rasagiline (2012) (6)
- GBA-associated PD: chances and obstacles for targeted treatment strategies (2022) (6)
- Effectiveness of botulinum neurotoxin type A injections in naïve and previously-treated patients suffering from Torti- or Laterocollis or -caput: Results from a German-Austrian open-label prospective post-marketing surveillance study (2019) (6)
- Patients’ perspective on current treatment options for Parkinson’s Disease (2017) (6)
- Torticaput versus Torticollis: Clinical Effects with Modified Classification and Muscle Selection (2019) (6)
- Levodopa–entacapone–carbidopa intestinal gel infusion in advanced Parkinson’s disease: real-world experience and practical guidance (2022) (6)
- Equivalent doses of ropinirole and bromocriptine (1999) (6)
- Tremor in Idiopathic Cervical Dystonia – Possible Implications for Botulinum Toxin Treatment Considering the Col-Cap Classification (2020) (6)
- Differential diagnosis of parkinsonism: a head-to-head comparison of FDG PET and MIBG scintigraphy (2020) (6)
- Dynamics of device-based treatments for Parkinson’s disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa–carbidopa intestinal gel, and deep brain stimulation (2019) (6)
- [Therapy of anal fissure using botulinum toxin: perianal thrombosis as a complication]. (1995) (6)
- [Diagnostic evaluation of the rectum and pelvic floor in chronic constipation]. (1999) (6)
- Use of Botulinum Neurotoxin in Parkinson’s Disease: A Critical Appraisal (2021) (6)
- Validity of the DESPAR questionnaire as a new screening tool for depression in Parkinson’s disease (2011) (5)
- Low-dosed Botulinum Toxin A in the Prophylactic Management of Unilateral Migraine: A Randomized Double-blind Placebo-Controlled Crossover Study (2011) (5)
- [Therapy of Hemifacial Spasm with Botulinum Toxin]. (2017) (5)
- Urethrismus accounting for voiding disorder. (1998) (5)
- [Disorders of eye movement in amyotrophic lateral sclerosis--report of 2 patients]. (1995) (5)
- Botulinum Toxin A in Anal Fissure: Why Does It Work? (2004) (5)
- What are the considerations for anti-hypertensive treatment in patients with Parkinson’s disease? (2020) (5)
- Riddle of the sphincters in anal fissure (1995) (5)
- Interkulturelle Adaption der AIMS in deutscher Sprache (2016) (5)
- Initial experience with ropinirole PR (prolonged release) (2008) (5)
- Bilateral Globus Pallidus Internus Deep Brain Stimulation in a Case of Progressive Dystonia in Mohr-Tranebjaerg Syndrome with Bilateral Cochlear Implants (2018) (4)
- Botulinum Toxin in Low Back Pain (2003) (4)
- Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus (2022) (4)
- Dose per muscle in cervical dystonia: pooled data from seven movement disorder centres. (2021) (4)
- [Sympathetic skin response in Parkinson syndrome]. (1995) (4)
- A critical review of incobotulinumtoxinA in the treatment of chronic sialorrhea in pediatric patients (2021) (4)
- High clinician- and patient-reported satisfaction with individualized onabotulinumtoxinA treatment for spasticity across several etiologies from the ASPIRE study (2020) (4)
- [S1-Guideline for Diagnosis and Treatment of Erectile Dysfunction]. (2019) (4)
- Assessing the burden of illness from cervical dystonia using the Toronto Western Spasmodic Torticollis Rating Scale scores and health utility: a meta-analysis of baseline patient-level clinical trial data (2014) (4)
- [Intercultural adaptation of the AIMS in German language: A scale for abnormal involuntary movements]. (2016) (4)
- [Long-term treatment of Lambert-Eaton syndrome by 3, 4 diaminopyridine]. (1992) (4)
- [Hypersalivation - Update of the S2k guideline (AWMF) in short form]. (2019) (4)
- [Practical use of continuous apomorphine infusion via pump]. (2017) (4)
- Potential Biomarkers of Parkinson's Disease (2007) (4)
- Medikamentöse Interaktionen in der Parkinson-Therapie (2003) (3)
- Influence of electrostimulation on the sphincteric compound muscle action potential in fecal incontinence (1997) (3)
- [Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study]. (2018) (3)
- Neurography of the pudendal nerve in pudendal canal syndrome (1999) (3)
- Botulinum Toxin in the Treatment of Migraine (2003) (3)
- An updated calculator for determining levodopa-equivalent dose (2021) (3)
- [Blood pressure and hormonal regulation in active and passive orthostasis]. (1995) (3)
- Torticaput versus Torticollis: Clinical Effects with Modified Classification and Muscle Selection (2019) (3)
- [Disorders of autonomic regulation in Parkinson syndrome]. (1995) (3)
- Validierung des NMSQuest in deutscher Sprache (2009) (3)
- [Blood pressure adaptation and hormone regulation in Parkinson patients following orthostasis]. (1996) (3)
- OnabotulinumtoxinA Treatment in Adults with Spasticity Reduces Caregiver Burden: Results from the ASPIRE Study (2019) (3)
- [Ergotamine-induced rectal lesions in asymptomatic patients]. (1994) (2)
- Are heart rate responses reproducible in the tilt-table test? (1994) (2)
- [Treatment of Sialorrhea with Botulinum Neurotoxin Type A - Consensus Practice Recommendations for Children and Adults]. (2022) (2)
- Early Diagnosis in Parkinson's Disease (2010) (2)
- [Electrophysiologic studies of fecal incontinence in the woman]. (1998) (2)
- Classification and Diagnosis of Cervical Dystonia: Revived Call for Consensus (2022) (2)
- [Depression in Parkinson's disease--Part 2: Therapy and management]. (2010) (2)
- Cerebral and extracranial neurodegeneration are strongly coupled in Parkinson's disease (2008) (2)
- [Practical Use of the Levodopa Pump]. (2016) (2)
- ‘Similar To’ Is Not ‘Identical With’, and ‘Identical With’ Is Not ‘The Same As’ (2015) (2)
- Evaluating Opicapone as Add-on Treatment to Levodopa/DDCI in Patients with Parkinson’s Disease (2022) (2)
- Duloxetine in the treatment of stress urinary (2005) (2)
- [Bladder dysfunctions in encephalomyelitis disseminata--drug and interventional therapeutic options]. (1995) (2)
- [The oral vitamin E tolerance test--an attempt at standardization]. (1999) (2)
- [Pharmacological treatment of motor symptoms in Parkinson's diseases]. (2017) (2)
- Commentary: Roles of the Cannabinoid System in the Basal Ganglia in Parkinson's Disease (2022) (2)
- Poster session Sessions 32: Methods in electrophysiologyA new method to determine pudendal nerve motor latency and central motor conduction time to the external anal sphincter (1993) (2)
- Randomized controlled trials on the use of cannabis-based medicines in movement disorders: a systematic review (2022) (2)
- [Indirect costs in idiopathic Parkinson's disease]. (2005) (2)
- Long‐Term Observational Results from the ASPIRE Study: OnabotulinumtoxinA Treatment for Adult Lower Limb Spasticity (2020) (2)
- Comment: Relevance of sonography for botulinum toxin treatment of cervical dystonia: An expert recommendation (2016) (2)
- [When should we start medical treatment in Parkinson disease]. (2010) (2)
- Botulinum neurotoxin in cervical dystonia revisited - recent advances and unanswered questions. (2021) (2)
- Diffusion microstructure imaging in progressive supranuclear palsy: reduced axonal volumes in the superior cerebellar peduncles, dentato-rubro-thalamic tracts, ventromedial thalami, and frontomesial white matter. (2022) (2)
- Poster 361 Impact of Early Intervention with OnabotulinumtoxinA Treatment in Adult Patients with Post‐Stroke Lower Limb Spasticity (2016) (2)
- [Therapy of Hemifacial Spasm with Botulinum Toxin]. (2019) (2)
- Basal Ganglia – A translational journal (2011) (1)
- Kindness in science does matter (2021) (1)
- Parkinsonian Drugs: Indications (2020) (1)
- [The history of Freezing-of-gait in Parkinson's disease - from phenomena to symptom]. (2020) (1)
- [Clinical data of the prolonged-release formulation of ropinirole]. (2010) (1)
- Time for a new definition of Parkinson’s disease (2019) (1)
- [Duodenale levodopa and apomorphine infusion for motor complications in advanced Parkinson's disease]. (2018) (1)
- The botulinum toxin legend of Reinhard Heydrich's death (2017) (1)
- Is cardiovascular dysregulation in idiopathic Parkinson's syndrome correlated with decreased hormonal release?; TO THE EDITOR (1997) (1)
- Treadmill training and physiotherapy similarly improve dual task gait performance: a randomized-controlled trial in Parkinson’s disease (2022) (1)
- [Functional studies of the autonomic nervous system]. (1993) (1)
- SIAXI: IncobotulinumtoxinA for sialorrhea in Parkinson’s disease, stroke, and other etiologies-Phase 3 Results (S30.007) (2018) (1)
- Karl Friedrich Bonhoeffer (1957) (1)
- The final diagnoses of patients with clinically suspected atypical parkinsonian syndromes. (2021) (1)
- Low-dosed botulinum toxin in migraine without aura: A randomized, double-blind placebo-controlled crossover study (2010) (1)
- Long-term efficacy and safety of incobotulinumtoxinA treatment for sialorrhea (2018) (1)
- Somatosensible Potenziale bei anorektalen Störungen (2006) (1)
- [Structure and efferences of the substantia nigra pars compacta in Parkinson's disease]. (2020) (1)
- Symptomatic medication of multiple system atrophy with predominant parkinsonism: Overview of 97 patients (2017) (1)
- Intra- and interindividual reproducibility of heart rate variations in the tilt-table test. (2000) (1)
- [Pharmacotherapy of stress incontinence]. (2005) (1)
- The Adult Spasticity International Registry (ASPIRE) study: 1 year results (2017) (1)
- The impact of bromocriptine on blood pressure, heart Rate and noradrenaline concentration after active orthostasis in Parkinson patients. (1997) (1)
- Should the maximum daily doses of levodopa be limited to 400 mg/die? (2014) (1)
- [Botulinumtoxin for bladder disorders]. (2019) (1)
- Abstract TMP34: OnabotulinumtoxinA Treatment in Post-stroke Lower Limb Spasticity: Long-term Results From a Phase 3 Study (2016) (1)
- Parkinson’s disease – Many diseases with many faces (2008) (1)
- Symptomatic medication of 97 patients with multiple system atrophy parkinsonian subtype: An observational study (2018) (1)
- Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease. (2014) (1)
- [Dystonia Non-Motor Symptoms Questionnaire (DNMSQuest) for assessment of non-motor symptoms in dystonia : Intercultural adaptation in the German language]. (2020) (1)
- Botulinumtoxin in the treatment of axillary hyperhidrosis – Longitudinal analysis (2010) (1)
- Treatment of dopa-responsive dystonia with Duodopa® (2012) (1)
- Principles of Transdermal Drug Delivery Systems for Treatment of Parkinson's Disease (2009) (1)
- Electrophysiologic testing of pelvic floor: some remarks. (2002) (1)
- How Do I Treat Cervical Dystonia With Botulinum Toxin by Using Ultrasound? (2017) (1)
- Ergotamininduzierte Rektumläsionen (1999) (1)
- Parkinson’s disease: a multi-faceted disease (2011) (1)
- Comment to Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease (2014) (1)
- [Autonomic dysregulations in Parkinson's syndrome]. (2005) (1)
- [Rational neurologic diagnosis in fecal incontinence]. (1992) (1)
- Characterization of advanced Parkinson’s disease in Germany: results of the non-interventional OBSERVE-PD study (2022) (1)
- Efficacy of incobotulinumtoxinA in subjects with sialorrhea, assessed using the modified radboud oral motor inventory for Parkinson's disease (mROMP) (2018) (1)
- Impact of early intervention with onabotulinumtoxinA treatment in adult patients with post-stroke lower limb spasticity: results from the double-blind, placebo-controlled, phase 3 REFLEX study (2020) (1)
- SPECT disclose complementary aspects of Parkinson's disease (2006) (1)
- [Help for patients with multiple sclerosis: current diagnostic and treatment possibilities in neurogenic disorders of bladder emptying]. (2008) (1)
- AbobotulinumtoxinA for the treatment of upper limb spasticity (2014) (1)
- Spasticity in practice (SPACE): an international non-interventional study of botulinum neurotoxin type A in treatment-naïve subjects with spasticity. (2021) (1)
- The dopaminergic system: an everlasting challenge. Editorial. (2006) (0)
- Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of entacapone: Findings from the real-world OPTIPARK study (2021) (0)
- Contents, Vol 34, 1994 (2004) (0)
- Workshop III: Late motor complications of Parkinson's disease (2000) (0)
- P133 Nonmotor fluctuations in Parkinson’s disease: Evaluation of frequency and severity of nonmotor symptoms in off states of advanced Parkinson’s disease (2011) (0)
- Time-course of decline in different cognitive domains in Parkinson’s disease: a retrospective study (2021) (0)
- Subject Index Vol. 34, 1994 (1994) (0)
- [Adenosine A2A Receptor Antagonists as a Treatment Option for Parkinson's Disease?] (2022) (0)
- OnabotulinumtoxinA Reduces Disability in Treatment-Naive Adult Patients with Spasticity: The ASPIRE Study (2019) (0)
- NEUROPHYSIOLOGISCHE DIAGNOSTIK IN DER PROKTOLOGIE (1997) (0)
- Negative Katalyse und Antiklopfmittel (1941) (0)
- Surgical treatment of dystonia (2014) (0)
- Comparison of onabotulinumtoxina utilization across various etiologies of spasticity from the Adult spasticity international registry study: ASPIRE (2018) (0)
- Management of sialorrhea (2018) (0)
- 8th Experts Meeting Parkinson's Disease (2007) (0)
- Comprehensive Care of Patients with Spastic Paresis – A Long-Term Commitment (2016) (0)
- Somatosensory evoked potentials of the pudendal nerve in penile hypoesthesia. Commentary (1998) (0)
- [The future of the Parkinson syndrome]. (2010) (0)
- Poster 68: IncobotulinumtoxinA for Sustained Improvement in Sialorrhea in Parkinson's Disease, Stroke, and Other Etiologies: Long‐term Results from a Phase 3 Study (2018) (0)
- Does botulinum toxin make sense in pain therapy? (2004) (0)
- [Treatment of end-of-dose fluctuations: the need for an individualized approach]. (2018) (0)
- [Constipation in neurological diseases]. (2000) (0)
- Impact of Early Intervention with OnabotulinumtoxinA Treatment in Adult Patients with Post-Stroke Lower Limb Spasticity (S31.006) (2016) (0)
- 13. Experten Meeting Parkinson (2007) (0)
- Botulinum neurotoxin in neurological practice - a leading topic in neurology. (2021) (0)
- [Lambert-Eaton syndrome]. (1996) (0)
- OnabotulinumtoxinA treatment utilization varies by etiology of spasticity, while maintaining high patient and clinician satisfaction: results from the aspire study (2018) (0)
- Attainment of physiologic salivary flow rate with long-term incobotulinumtoxinA treatment for sialorrhea in Parkinson's disease and other neurologic conditions (2020) (0)
- [Potential antinociceptive mechanisms of botulinum toxin]. (2006) (0)
- Parkinson’s disease—an everlasting challenge (2004) (0)
- Drugs in the Treatment of Dystonia, Multisystem Atrophy, and Non-Parkinson Tremor (2020) (0)
- First experience with safinamide in clinical practice (2017) (0)
- [Complexity of Parkinson Syndrome]. (2016) (0)
- Influence of onset of motor fluctuations on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: Findings from the real-world OPTIPARK study (2021) (0)
- Incidence of dystonia related to COVID-19 infection. (2023) (0)
- Poster 75: Exploring Real‐World OnabotulinumtoxinA Utilization Patterns for the Treatment of Lower Limb Spasticity: The Adult Spasticity International Registry (ASPIRE) Study (2018) (0)
- Therapy for Migraine with Almotriptane (2008) (0)
- 2.249 EFFICACY OF RASAGILINE IN COMBINATION WITH DOPAMINE AGONIST THERAPY: RESULTS FROM A POST-MARKETING OBSERVATIONAL STUDY IN PATIENTS WITH PARKINSON'S DISEASE (2012) (0)
- Abstracts Second Congress of the European Society for Clinical Neuropharmacology (1995) (0)
- German Guidelines for the Use of Parkinsonian Drugs (2021) (0)
- Smoking behavior and idiopathic Parkinson's syndrome (2017) (0)
- Early Intervention in Parkinson's Disease with Cabergoline – Results of an Open-Label Long-Term Trial with Focus on Sleep Disturbances (2006) (0)
- King’s Parkinson’s Disease Pain Scale--German Version (2019) (0)
- Sleep in patients with Parkinson's disease: Differences in two groups of 219 patients with and without sleep disturbances (2017) (0)
- [Botulinum toxin in tension-type headache]. (2003) (0)
- Time for a change (2016) (0)
- [New Therapeutic Options for the Individualised Titration of Levodopa]. (2020) (0)
- An international, noninterventional study of botulinum neurotoxin type A in treatment-naive subjects with spasticity (2018) (0)
- Baseline Demographics and Clinical Characteristics of Patients Treated for Spasticity in the Adult Spasticity International Registry (ASPIRE Study) (P3.296) (2016) (0)
- onabotulinumtoxina treatment in adult patients with post-stroke lower limb spasticity: Results from a double-blind, placebo-controlled, phase 3 clinical trial : o2.2 (2015) (0)
- EditorialLate or early treatment in Parkinson's disease? (2013) (0)
- Influence of levodopa on orthostatic hypotension in Parkinson's disease (2020) (0)
- Poster 66: The Adult Spasticity International Registry (ASPIRE) Study: Treatment Utilization Patterns in Patients Treated for Both Upper and Lower Limb Spasticity (2017) (0)
- [Therapy of sialorrhea with botulinum toxin]. (2019) (0)
- Individualized onabotulinumtoxinA treatment for upper limb spasticity resulted in high patient and clinician satisfaction in the aspire study (2018) (0)
- [Response to the letter by Dr.-H. Zermann on the contribution by W.H. Jost, "Value of electromyography in diagnosis of incontinence"]. (1997) (0)
- Poster 471: SIAXI: Efficacy and Safety of IncobotulinumtoxinA for the Treatment of Sialorrhea in Parkinson's Disease (PD), Stroke, and Other Neurological Conditions: Results of a Phase III, Placebo‐Controlled, Randomized, Double‐Blind Study (2017) (0)
- Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy (2021) (0)
- Is It Meanwhile Biomedical Sciences or Still “Ars Medica”? (2020) (0)
- Long-term Efficacy and Safety of IncobotulinumtoxinA Treatment for Sialorrhea (S4.007) (2019) (0)
- [Value of electromyography in diagnosis of incontinence]. (1996) (0)
- Individualized onabotulinumtoxinA treatment for lower limb spasticity resulted in high patient and clinician satisfaction in the aspire study (2018) (0)
- Early Diagnosis in Parkinson’s Disease: Fact or Fiction? (2010) (0)
- Treatment of Patients With Upper Limb and Lower Limb Spasticity With OnabotulinumtoxinA in the Adult Spasticity International Registry (ASPIRE) (2022) (0)
- Just new problems, or their solution? (2011) (0)
- Poster 56: Exploring Real‐World OnabotulinumtoxinA Utilization Patterns for the Treatment of Upper Limb Spasticity: The Adult Spasticity International Registry (ASPIRE) Study (2018) (0)
- The SYNAPSES study (StudY to observe SafiNAmide in clinical Practice during the firSt post-commErcialization phaSe): Methodology and feasibility (2017) (0)
- PO25-TH-06 No secondary treatment failure with Xeomin© (2009) (0)
- Impact of early intervention with onabotulinumtoxinA treatment in adult patients with poststroke lower limb spasticity (2016) (0)
- Clinical data on the prolonged-release formulation of ropinirole for Parkinson’s disease (2011) (0)
- A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial. (2021) (0)
- Rotigotine for Treating Parkinson’s Disease (2020) (0)
- An examination of real-world onabotulinumtoxina utilization for the treatment of lower limb spasticity: The Adult Spasticity International Registry (ASPIRE) study (2018) (0)
- Cervical dystonia in Parkinson's Disease: frequency of occurrence and subtypes. (2022) (0)
- Impulse control disorder and punding arising in a patient treated with levodopa (2010) (0)
- 1.100 Early diagnosis for Parkinson's disease according to whole blood gene profile (2007) (0)
- Neurology meets Psychiatry (2008) (0)
- SIAXI: IncobotulinumtoxinA for Sialorrhea in Parkinson's Disease, Stroke, and Other Etiologies-Phase III Results (2017) (0)
- [Triple combination of levodopa, carbidopa and entacapone by intrajejunal pump in advanced Parkinson's disease]. (2022) (0)
- Are further national Expert Meetings called for today (2014) (0)
- [Use of botulinum toxin in urology]. (2008) (0)
- 2.216 Rasagiline in daily clinical use – a post-marketing observational study in Parkinsonian patients receiving combination therapy shows good efficacy and tolerability (2007) (0)
- The influence of relaxation techniques and sports on disability and therapeutic effect in patients with cervical dystonia: Results of an online survey (2017) (0)
- [Therapy of Sialorrhea with Botulinum Toxin - An Update]. (2022) (0)
- Basal Ganglia and DPG (German Parkinson Society) (2011) (0)
- SIAXI: Efficacy and safety of Xeomin (incobotulinumtoxinA) for the treatment of sialorrhea in Parkinson’s disease (PD) and other neurological conditions: Results of a Phase III, placebo-controlled, randomized, double-blind study (S2.007) (2018) (0)
- [Neurophysiologic diagnosis in proctology]. (1997) (0)
- Rasagiline in Parkinson's disease: the show must go on (2013) (0)
- If you can't be with the one you love, love the one you're with (C, S, N & Y) (2023) (0)
- Neurophysiological Diagnostics for Anal Incontinence and Constipation (2011) (0)
- P155 Clozapine induced parkinsonism: A case report (2011) (0)
- Validation of a German version of the NMSS (Non-Motor Symptom assessment Scale) (2010) (0)
- MAO-B inhibitors: The questioning never stops (2012) (0)
- [20th Experten Meeting Parkinson]. (2020) (0)
- Impact of injection guidance techniques on the efficacy and safety of incobotulinumtoxinA for sialorrhea (2018) (0)
- Movement Disorders: More than just Parkinson’s disease (2017) (0)
- 122. Cerebral and extracranial neurodegeneration are strongly coupled in Parkinson’s disease (2009) (0)
- Abstracts: Satellite symposium (2005) (0)
- OnabotulinumtoxinA Treatment in Patients with Upper Limb and Lower Limb Spasticity from the ASPIRE Study (2021) (0)
- 1.011 Early diagnosis for Parkinson's disease according to whole blood gene profile (2007) (0)
- [Routine diagnosis of disorders of autonomic regulation. References for implementation and evaluation]. (1993) (0)
- P154 Dopamine transporter scan in normal pressure hydrocephalus (2011) (0)
- [Botulinum toxin in pain therapy]. (2007) (0)
- Reply to: Sudden Death In Parkinson´s Disease: Treating Hypertension In The Elderly (2020) (0)
- A novel treatment option for intrajejunal levodopa administration (2023) (0)
- P107 Piribedil (CLARIUM®) monotherapy in young de-novo patients with Parkinson’s Disease – Subgroup analysis of two prospective, non-interventional observational studies (2011) (0)
- Early intervention in parkinson’s disease with cabergoline – Results of an open-label long-term trial with focus on sleep disturbances (2007) (0)
- 113. Treatment of head tremor with botulinum toxin (2015) (0)
- Optimised endoscopic access for intrajejunal levodopa application in idiopathic Parkinson's syndrome. (2023) (0)
- Efficacy and safety of incobotulinumtoxinA for the treatment of sialorrhea: Results of the main phase of a phase 3 study (2018) (0)
- [Correction: Treatment of Sialorrhea with Botulinum Neurotoxin Type A - Consensus Practice Recommendations for Children and Adults]. (2022) (0)
- Somatosensory evoked potentials in neuro-proctology (2006) (0)
- Electrophysiologic testing of pelvic floor: Some remarks. Author's reply (2002) (0)
- Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of dopamine agonists: Findings from the real-world OPTIPARK study (2021) (0)
- Real-World Use of OnabotulinumtoxinA for Lower Limb Spasticity: Adult Spasticity International Registry (ASPIRE) (2018) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Wolfgang H. Jost?
Wolfgang H. Jost is affiliated with the following schools: